Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in their interests in the company's Ordinary shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director shareholdings rather than a financial performance report.
Material Changes
On December 30, 2011, the company's Non-Executive Directors were provisionally allocated awards over Ordinary shares and ADSs through the annual reinvestment of dividends paid throughout 2011. These allocations were confirmed to the company and directors on January 3, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director transactions.
Important Facts for Investors
- Transaction Type: Annual dividend reinvestment awards for Non-Executive Directors.
- Transaction Date: Allocated December 30, 2011; notified January 3, 2012.
- Share Classes: Awards were issued in both Ordinary shares (average price £14.70) and ADSs (average price $45.53).
- Participants: Includes Sir Christopher Gent, Prof Sir Roy Anderson, Dr Stephanie Burns, Ms Stacey Cartwright, Mr Lawrence Culp, Sir Crispin Davis, Ms Judy Lewent, Sir Deryck Maughan, Mr James Murdoch, Dr Daniel Podolsky, Mr Tom de Swaan, and Sir Robert Wilson.
- Financial Data: No operational or financial performance data is included in this specific filing.